QL1706 + paclitaxel + cisplatin + carboplatin

QL1706 + paclitaxel + cisplatin + carboplatin is a multi-agent chemotherapy and immunotherapy regimen that consists of QL1706, paclitaxel, cisplatin, and carboplatin. - **QL1706** is a novel bispecific monoclonal antibody engineered to target both PD-1 (programmed cell death protein 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), serving as a dual immune checkpoint inhibitor[3][5][7]. - **Paclitaxel** is a chemotherapeutic agent that stabilizes microtubules, disrupting cell division. - **Cisplatin** and **carboplatin** are platinum-based chemotherapies that bind to and crosslink DNA, causing apoptosis in rapidly dividing cancer cells[2][4][6][8]. This combination is designed to leverage both immunomodulatory and cytotoxic mechanisms to enhance antitumor activity, primarily investigated in the setting of solid tumors such as non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), cervical cancer, and ovarian cancer[3][5][7]. QL1706 was developed by Shanghai Qilu Pharmaceutical and has shown promising preliminary efficacy when combined with platinum and taxane chemotherapy[5][7].